|Molecular Weight||Approximately 15.4 kDa, a single non-glycosylated polypeptide chain containing 133 amino acids.|
|AA Sequence||QGQDRHMIRM RQLIDIVDQL KNYVNDLVPE FLPAPEDVET NCEWSAFSCF QKAQLKSANT GNNERIINVS IKKLKRKPPS TNAGRRQKHR LTCPSCDSYE KKPPKEFLER FKSLLQKMIH QHLSSRTHGS EDS|
|Purity||> 98 % by SDS-PAGE and HPLC analyses.|
|Biological Activity||Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using human N1186 T cells is less than 20 ng/ml, corresponding to a specific activity of > 5.0 × 104 IU/mg.|
|Physical Appearance||Sterile Filtered White lyophilized (freeze-dried) powder.|
|Formulation||Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.|
|Endotoxin||Less than 0.01 EU/µg of rHuIL-21 GMP as determined by LAL method.|
|Reconstitution||We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.|
|Stability & Storage||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
3 months, -20 to -70 °C under sterile conditions after reconstitution.
|Usage||This GMP product can be for research use or further manufacturing use.|
|Quality statement||The manufacture and testing of this product is in compliance with ICH Q7a guidelines.|
|Reference||1. Pistoia VandCocco C. 2009. J Leukoc Biol, 85: 739-43.|
2. Ertelt JM, Johanns TM, Rowe JH, et al. 2010. Immunology, 131: 183-91.
3. Denman CJ, Senyukov VV, Somanchi SS, et al. 2012. PLoS One, 7: e30264.
4. Spolski R, Wang L, Wan CK, et al. 2012. J Immunol, 188: 1924-32.
|Background||Human IL-21 is encoded by IL-21 gene located on Chr. 4. It is a pleiotropic cytokine produced by CD4+ T cells in response to antigenic stimulation and can regulating immune system cells, for instance cytotoxin T cells and natural killer cells. Additionally, it can induce target cells division or proliferation. IL-21 elicits its effect through binding to IL-21R, which also contains the gamma chain found in other cytokine receptors such as IL-2, IL-4, IL-7, IL-9 and IL-15. IL-21/IL-21R interaction triggers a cascade of events which includes activation of the tyrosine kinases JAK1 and JAK3, followed by activation of the transcription factors STAT1 and STAT3. IL-21 shows having much relation with clinical illnesses, including cancer immunotherapy, viral infections and allergies.|